Skip to main content
Premium Trial:

Request an Annual Quote

Rarecell's CTC/CTM Technology Chosen for Study into Prostate Cancer

NEW YORK (GenomeWeb News) – French biotechnology firm Rarecells today announced that Ipsen and Institut Gustave Roussy, has selected its ISET technology for a study into patients with prostate cancer.

The technology is for circulating tumor cell and circulating tumor microemboli isolation.

The goal of the study is to use ISET, which stands for Isolation by Size of Epithelial/Throphoblastic Tumor cells, for the molecular analysis and genetic characterization of circulating cancer cells, Rarecells said.

"CTCs captured as a liquid biopsy from blood are expected to provide increasingly important clinical information on therapy choice, effectiveness, and drug resistance," Françoise Farace, head of the Circulating Cells Laboratory at Institut Gustave Roussy, said in a statement. "ISET is a powerful tool for capturing high levels of CTCs and [exploiting] them as a predictive biomarker in the context of personalized anticancer treatments."

Terms of the deal were not disclosed.

Based in Paris, Rarecells was founded in 2009 to commercialize the ISET technology

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more